

1 Carriage duration of carbapenemase-producing *Enterobacteriaceae* in a hospital cohort -
2 implications for infection control measures

3

4

5 Yin Mo^{1,2,3*#}, Anastasia Hernandez-Koutoucheva^{1*}, Patrick Musicha^{1,4}, Denis Bertrand⁵, David
6 Lye^{3,6,7,8}, Ng Oon Tek^{6,7,8}, Shannon N. Fenlon⁵, Swaine L. Chen^{3,5}, Ling Moi Lin⁹, Wen Ying
7 Tang¹⁰, Timothy Barkham¹⁰, Niranjana Nagarajan^{3,5}, Ben S Cooper^{1,4}, Kalisvar Marimuthu^{3,6,7}

8

- 9 1. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
10 Mahidol University, 3/F, 60th Anniversary Chalermprakit Building, 420/6 Rajvithi
11 Road, Bangkok, Thailand, 10400
- 12 2. Division of Infectious Diseases, University Medicine Cluster, National University
13 Hospital, 5 Lower Kent Ridge Road, Singapore, 119074
- 14 3. Department of Medicine, Yong Loo Lin School of Medicine, National University of
15 Singapore, 1E Kent Ridge Road, Singapore 119228
- 16 4. Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford,
17 Old Road Campus, Headington, Oxford, United Kingdom, OX3 7BN
- 18 5. Genome Institute of Singapore, 60 Biopolis Street, Singapore 138672
- 19 6. Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
- 20 7. National Centre for Infectious Diseases, Singapore
- 21 8. Lee Kong Chian School of Medicine, Nanyang Technological University
- 22 9. Infection Prevention & Epidemiology, Singapore General Hospital
- 23 10. Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, 308433

24

25 * Authors contributed equally to the manuscript

26 # Address correspondence to Mo Yin: yin_mo@nuhs.edu.sg

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 Abstract

48 Carriage duration of carbapenemase-producing *Enterobacteriaceae* (CPE) is uncertain. We
49 followed 21 CPE carriers over one year. Mean carriage duration was 86 (95%CrI= [60, 122])
50 days, with 98.5% (95%CrI= [95.0, 99.8]) probability of decolonization in one year. Antibiotic
51 consumption was associated with prolonged carriage. CPE-carriers' status should be reviewed
52 yearly.

53

54 Introduction

55 The rapid global dissemination of carbapenemase-producing *Enterobacteriaceae* (CPE) poses a
56 public health threat [1]. The lack of effective therapy is associated with high mortality and
57 healthcare costs [1]. Infection prevention and control are important measures to prevent the
58 spread of CPE to vulnerable patients.

59

60 Early identification, isolation, and contact precautions are advocated by international guidelines
61 to prevent the spread of CPE in healthcare settings [2,3]. Understanding the natural history and
62 duration of CPE carriage will help in the design of rational infection control policies. In this
63 study, we estimate carriage duration of CPE in a hospital cohort and identify risk factors for
64 prolonged carriage.

65

66 Methods

67 We conducted a prospective cohort study involving CPE carriers from October 2016 to February
68 2018. Study participants were recruited from two tertiary centers with over 1600 beds in
69 Singapore. All admitted patients above 21 years with prior hospitalization within 12 months were

70 screened for CPE carriage. We collected stool samples from study participants on enrolment,
71 weekly for four weeks, monthly for five months, then bimonthly for six months. Demographic
72 characteristics, healthcare contact and medication history were recorded. The study received
73 ethics approval from the Singapore National Healthcare Group Domain Specific Review Board
74 (NHG DSRB Reference: 2016/00364) prior to commencement.

75
76 Stool samples were inoculated onto selective chromogenic agar (ChromID Carba SMART), and
77 species identification was done with matrix assisted laser desorption ionization-time of flight-
78 mass spectrometry (MALDI-ToF (Bruker)). Antibiotic susceptibility testing was performed
79 using VITEK-2. All *Enterobacteriaceae* isolates with a minimum inhibitory concentration of
80 ≥ 2 mg/L for meropenem, or ≥ 1.0 mg/L for ertapenem, underwent polymerase chain reaction
81 (PCR) for the presence of *bla*_{NDM-1}, *bla*_{KPC}, *bla*_{OXA-48}, *bla*_{IMI-1} and *bla*_{IMP} genes [4]. All CPE
82 isolates and stool DNA underwent sequencing on the Illumina HiSeq 4000 sequencer. The
83 Shannon diversity index was used to measure α -diversity for stool microbial communities [5].

84
85 We analyzed the data with Bayesian multi-state Markov models to account for interval censoring
86 (Supplementary material). First, we estimated the overall transmission rates by considering
87 patients to be in either CPE colonized or non-colonized states. Secondly, we considered CPE
88 colonization on a species level, and included CP-*Escherichia coli* (CP-EC) colonized, CP-
89 *Klebsiella pneumoniae* (CP-KP) colonized, CP-EC/KP co-colonized as separate states
90 (Supplementary figure 1). All analyses were performed using R 3.4.4 and RStan [6,7].

91

92 Results

93 Twenty-one patients were enrolled with a mean follow-up period of 294 (SD=77) days, and each
94 participant provided 12 (SD=1.5) samples. Patient details on demographics and medical history
95 are in Table 1.

96
97 Throughout follow-up, 15/21 (71.4%) participants carried more than one species of CPE, while
98 only 3/21 (14.3%) participants carried more than one type of carbapenemase genes (χ^2 of
99 difference in proportions=14.8, simulated p-value=0.0005) (Supplementary table 1). The most
100 common species carried by the participants were *K. pneumoniae* (18/21, 85.7%) and *E. coli*
101 (16/21, 76.2%). The most frequently observed carbapenemase genes were OXA-48 (11/21,
102 52.4%) and KPC (8/21, 38.1%). Seventy-six CP-KP were isolated from the samples, out of
103 which sequence type (ST) 307 (25/76, 32.9%) was the most common. Amongst the CP-EC
104 isolates, ST131 (22/83, 26.5%) was the most common. Most participants (17/21, 81.0%) had
105 continuously positive samples until clearance. Four participants had negative samples followed
106 by positive samples, with the longest period being three negative samples over three consecutive
107 weeks (Figure 1).

108
109 The estimated mean duration of CPE carriage was 86 (95%CrI= [60, 122]) days. The probability
110 of decolonization was 98.5% (95%CrI= [95.0, 99.8]) in one year, assuming a constant
111 decolonization rate within the time interval. The longest observed carriage duration was 387
112 days. We analyzed age, co-colonization with other multidrug resistant organisms, presence of
113 urinary catheter, antibiotic use during follow up, Charlson comorbidity index, re-admission, and
114 Shannon diversity index as covariates to explore their association with decolonization
115 (Supplementary Figure 2). Antibiotic use during follow up was the only factor associated with

116 prolonged CPE carriage (HR= 0.48, 95%CrI= [0.20,0.93]). The rate of decolonization from CP-
117 EC was lower than that of CP-KP (0.018/day, 95%CI=[0.007,0.031] versus 0.030/day,
118 95%CI=[0.016, 0.049]) (Supplementary table 2 and figure 3).

119

120 Discussion

121 CPE infections are typically preceded by asymptomatic carriage, especially in vulnerable
122 patients such as the immunocompromised and critically ill [8]. Active surveillance to identify
123 CPE carriers is essential to prevent transmissions, but may be associated with high cost-benefit
124 ratio if implemented without understanding the natural history of CPE carriage.

125

126 Previous reports of CPE carriage duration are highly varied, with median duration ranging from
127 43 days to 295 days[8,9]. This is likely due to different follow-up schedules, microbiological and
128 molecular methods used to identify CPE, and criteria to define clearance. Studies that reported
129 longer carriage duration tended to adopt an opportunistic sampling strategy, and considered both
130 clinical and stool samples to determine carriage [9]. Opportunistic sampling may lead to
131 selection bias as patients with more healthcare contacts would have more samples taken.
132 Infrequent and inconsistent sampling is more likely to misclassify re-colonization from a new
133 transmission event as continuous colonization, resulting in perceived longer duration of carriage.

134

135 Our systematic sampling and robust methods to identify CPE allowed us to closely follow the
136 participants' carriage status. With combined detection methods of culture on carbapenem-
137 resistance selective media, antibiotic susceptibility testing and PCR, we found that a proportion
138 of patients (4/21, 19.0%) had intervening negative samples, ranging from one to three weeks

139 apart. To confidently declare eradication, a patient should have at least two negative samples
140 four to six weeks apart. Given that the probability of decolonization is 98.5% in one year, we
141 suggest that CPE carriers status should be maintained for one year. Further health economics
142 analysis is needed to make institution-specific recommendations on frequency of re-screening.
143 Given the finding that antibiotic use was the most important factor associated with prolonged
144 CPE carriage, antibiotics should be avoided if not clinically indicated.

145
146 An interesting finding is that the participants carried more species of CPE than types of
147 carbapenemase genes. While this may be due to new acquisition events, this observation is more
148 parsimoniously explained by active interspecies horizontal gene transfer especially in a low-
149 transmission setting such as in Singapore. Differential rate of clearance of CP-KP and CP-EC
150 can be related to colonizing affinity of the species and fitness cost of carbapenemase genes,
151 which are highly variable amongst different species [10]. Further studies incorporating both
152 between and within host transmission dynamics of resistance will be important to shed light on
153 the roles of bacterial clones and plasmids in spreading and maintaining resistance.

154
155 A limitation of the study is that the participants were screened after hospital admission and the
156 time of initial colonization could not be confidently determined. However, a recent survey of the
157 Singapore community showed that none out of 305 community dwellers carried CPE in their
158 stools [11]. Therefore, the likelihood that the participants were already colonized by CPE in the
159 community is low. Though our sample size is relatively small, to our knowledge, this study is the
160 most rigorously conducted in terms of frequency of stool sample collection, duration of follow

161 up, and number of participants in a non-outbreak setting. The use of multistate models has been
162 shown to preserve power with modest sample size given more frequent follow-ups [12].

163

164 Role of funding

165 The study is primarily supported by the Singapore Biomedical Research Council- Economic
166 Development Board Industry alignment fund (Grant ref: IAF311018). MY is supported by the
167 Singapore National Medical Research Council Research Fellowship (Grant ref:
168 NMRC/Fellowship/0051/2017). BSC is supported by UK Medical Research Council /
169 Department for International Development (Grant ref: MR/K006924/1). PM is supported by the
170 JPI-AMR (MODERN) (Grant ref: C-17-0014). AH is supported by Wellcome Trust (Grant ref:
171 212630/Z/18/Z). The Mahidol-Oxford Tropical Medicine Research Unit is part of the Wellcome-
172 Trust Major Overseas Programme in SE Asia (Grant ref: 106698/Z/14/Z). Additional grant
173 support was provided by the NMRC Clinician-Scientist Individual Research Grant (Grant ref:
174 NMRC/CIRG/1463/2016 and NMRC/CIRG/1467/2017) , Singapore Ministry of Education
175 Academic Research Fund Tier 2 grant: New Delhi Metallo-Beta-Lactamase: A global multi-
176 centre, whole-genome study (Grant ref: MOE2015-T2-2-096), NMRC Collaborative Grant:
177 Collaborative Solutions Targeting Antimicrobial Resistance Threats in Health Systems
178 (CoSTAR-HS) (Grant ref: NMRC CGAug16C005), NMRC Clinician Scientist Award (Grant
179 ref: NMRC/CSA-INV/0002/2016).

180

181 Acknowledgement

182 All of the authors have no conflict of interest to declare.

183

184 References

- 185 1. Logan LK, Weinstein RA. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae:
186 The Impact and Evolution of a Global Menace. *J Infect Dis* **2017**; 215:S28–S36.
- 187 2. Magiorakos AP, Burns K, Rodríguez Baño J, et al. Infection prevention and control
188 measures and tools for the prevention of entry of carbapenem-resistant into healthcare
189 settings: guidance from the European Centre for Disease Prevention and Control.
190 *Antimicrob Resist Infect Control* **2017**; 6:113.
- 191 3. Centers for Disease Control and Prevention, US. Facility Guidance for Control of
192 Carbapenem-resistant Enterobacteriaceae (CRE) – November 2015 Update CRE Toolkit.
193 2015. Available at: <https://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html>. Accessed
194 7 March 2019.
- 195 4. Teo JWP, La M-V, Krishnan P, Ang B, Jureen R, Lin RTP. Enterobacter cloacae producing
196 an uncommon class A carbapenemase, IMI-1, from Singapore. *J Med Microbiol* **2013**;
197 62:1086–1088.
- 198 5. Jari Oksanen, F. Guillaume Blanchet, Michael Friendly, Roeland Kindt, Pierre Legendre,
199 Dan McGlenn, Peter R. Minchin, R. B. O’Hara, Gavin L. Simpson, Peter Solymos, M.
200 Henry H. Stevens, Eduard Szoecs, Helene Wagner. Community Ecology Package.
201 Available at: <https://cran.r-project.org/web/packages/vegan/vegan.pdf>. Accessed 7 March
202 2019.
- 203 6. R Core Team. R: A Language and Environment for Statistical Computing. 2018. Available
204 at: <https://www.R-project.org/>.

- 205 7. Stan Development Team. RStan: the R interface to Stan. 2018; Available at: [http://mc-](http://mc-stan.org/)
206 [stan.org/](http://mc-stan.org/).
- 207 8. Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with
208 carbapenem-resistant Enterobacteriaceae: A systematic review. *Am J Infect Control* **2016**;
209 44:539–543.
- 210 9. Bar-Yoseph H, Hussein K, Braun E, Paul M. Natural history and decolonization strategies
211 for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-
212 analysis. *J Antimicrob Chemother* **2016**; 71:2729–2739.
- 213 10. Cerqueira GC, Earl AM, Ernst CM, et al. Multi-institute analysis of carbapenem resistance
214 reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. *Proc*
215 *Natl Acad Sci U S A* **2017**; 114:1135–1140.
- 216 11. Mo Y, Seah I, Lye PSP, et al. Relating knowledge, attitude and practice of antibiotic use to
217 extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage: results of a
218 cross-sectional community survey. *BMJ Open* **2019**; 9:e023859.
- 219 12. Cassarly C, Martin RH, Chimowitz M, Peña EA, Ramakrishnan V, Palesch YY. Assessing
220 Type I error and power of multistate Markov models for panel data—A simulation study.
221 *Communications in Statistics - Simulation and Computation*. 2017; 46:7040–7061.
222 Available at: <http://dx.doi.org/10.1080/03610918.2016.1222425>.

223

224


225

226

227

228 Figure 1. Types of CPE and plasmid colonization for study participants

229



230

231 Figure 1 depicts the microbiological outcomes of stool samples for each participant. Each

232 column of dots represents one stool sample. Each dot represents an *Enterobacteriaceae* species,

233 including *Klebsiella spp.*, *E coli*, *Enterobacter spp.* and *Citrobacter spp.*, yielded in the stool

234 samples carrying CPE genes. Missing data is shown by the absence of dots on a particular week.

235

236

237

238

239 Table 1. Participant demographics

Characteristics		n=21
Age (median, IQR^)		60.0 (50.0-69.0)
Female (%)		6 (28.6)
Ethnicity (%)	Chinese	15 (71.4)
	Malay	3 (14.3)
	Indian	2 (9.5)
	Others	1 (4.8)
Charlson comorbidity index (median, IQR^)		3.0 (2.0-5.0)
Ambulatory status (%)	Independent in ADL*	12 (57.1)
	Requires assistance in ADL	4 (19.0)
	Wheelchair bound	3 (14.3)
	Bed bound	2 (9.5)

Recent surgery (%)		15 (71.4)
Colonization or infection by another MDRO# in the preceding one year from enrolment		4 (19.0)
Hospitalization in the past 1 year (%)		11 (52.4)
Antibiotic intake during period of follow up (%)		13 (61.9)
Readmission during follow up (%)		10 (47.6)
Recent overseas travel (%)		13 (61.9)

240 ^ IQR: Interquartile range

241 *ADL: Activities of daily living

242 #MDRO: Multidrug resistant organisms including methicillin-resistant *Staphylococcus aureus*,
 243 vancomycin-resistant *Enterococcus*, carbapenem-resistant *Enterobacteriaceae*, carbapenem-
 244 resistant *Acinetobacter baumannii* and carbapenem-resistant *Pseudomonas aeruginosa*.

245

246 **Supplementary material**

247

248 Supplementary material 1: Methodology

249

250 Microbiology

251 Microbiological cultures to identify CPE were performed via direct inoculation of stool samples
252 onto selective and indicative agar, chromID® CARBA SMART Agar (CARB/OXA,
253 Biomerieux). After overnight incubation, colonies were identified at the species level with matrix
254 assisted laser desorption ionization-time of flight-mass spectrometry (MALDI-ToF-MS, Bruker
255 Daltonics GmbH, Bremen, Germany). Phenotypic antimicrobial susceptibility testing was
256 performed using VITEK-2 (bioMérieux Vitek, Inc., Hazelwood, MO). All *Enterobacteriaceae*
257 isolates with a minimum inhibitory concentration to meropenem $\geq 2\text{mg/L}$, or Ertapenem MIC
258 $\geq 1.0\text{mg/L}$, underwent polymerase chain reaction (PCR) to test for the presence of blaNDM-1,
259 blaKPC (blaKPC-2 to blaKPC-13), blaOXA48, blaIMI-1 and blaIMP carbapenemase genes, as
260 previously reported. (Teo *et al*, Singapore J Med Microbiol. 2013)

261

262 Genomic analysis

263 Library preparation for DNA from CPE isolates was performed using the NEBNext® Ultra™
264 DNA Library Prep Kit for Illumina®. Sequencing with 2x151bp reads was performed using the
265 Illumina HiSeq 4000 sequencer.

266

267 Raw FASTQ reads were processed using standard in-house pipelines. Briefly, MLST and
268 antibiotic resistance genes were called directly from raw reads as well as from *de novo*
269 assemblies; discrepancies between these were resolved with manual examination of both types of
270 data. For analysis of raw reads, MLST and antibiotic resistance genes were called directly from
271 the FASTQ files using SRST2 (version 0.1.8) (Inouye *et al*, Genome Med. 2014) with default
272 settings using the ARGannot database provided with the SRST2 distribution for resistance
273 genes. *De novo* assemblies were performed using the Velvet assembler (version 1.2.10) (Zerbino

274 *et al*, Genome Res. 2008) with parameters optimized by the Velvet Optimiser script packaged
275 with the velvet distribution, scaffolded with Opera (version 1.4.1) (Gao *et al*, J Comput Biol.
276 2011), and finished with FinIS (version 0.3) (Gao *et al*, Algorithms in Bioinformatics 2012).
277 Genomes were annotated with Prokka (version 1.11) (Seemann *et al*, Bioinformatics. 2014). For
278 analysis of *de novo* assemblies, resistance genes were called using BLASTN with a minimum
279 identity of 90% over 90% of the gene length required for calling a gene present, using the same
280 ARGAnnot database as used by SRST2. MLST calls were made by using a custom BLASTN-
281 based MLST caller. The MLST databases were downloaded using the SRST2 helper scripts from
282 <https://pubmlst.org>.

283

284 Shotgun metagenomics

285 DNA from stool samples was extracted using PowerSoil® DNA Isolation Kit (12888, MOBIO
286 Laboratories) with modifications to the manufacturer's protocol. To avoid spin filter clogging,
287 we extended the centrifugation to twice the original duration and solutions C2, C3 and C4 were
288 doubled in volume. DNA was eluted in 80µL of Solution C6. Concentration of DNA was
289 determined by Qubit dsDNA BR assay (Q32853, Thermo Fisher Scientific). For the library
290 construction, 50ng of DNA was re-suspended in a total volume of 50µL and was sheared using
291 Adaptive Focused Acoustics™ (Covaris) with the following parameters; Duty Factor: 30%, Peak
292 Incident Power (PIP): 450, 200 cycles per burst, Treatment Time: 240s. Sheared DNA was
293 cleaned up with 1.5× Agencourt AMPure XP beads (A63882, Beckman Coulter). Gene Read
294 DNA Library I Core Kit (180434, Qiagen) was used for end-repair, A-addition and adapter
295 ligation. Custom barcode adapters (HPLC purified, double stranded, 1st strand: 5' P-
296 GATCGGAAGAGCACACGTCT; 2nd strand: 5'

297 ACACTCTTTCCCTACACGACGCTCTTCCGATCT) were used in replacement of Gene Read
298 Adapter I Set for library preparation. Library was cleaned up twice using 1.5× Agencourt
299 AMPure XP beads (A63882, Beckman Coulter). Enrichment was carried out with indexed-
300 primers according to an adapted protocol from Multiplexing Sample Preparation Oligonucleotide
301 kit (Illumina). We pooled the enriched libraries in equi-molarity and sequenced them on an
302 Illumina HiSeq sequencing instrument to generate 2×101 bp reads, yielding 17,744 million
303 paired-end reads in total and 49 million paired-end reads on average per library.

304
305 Reads were processed with an in-house shotgun metagenomics data analysis pipeline
306 (<https://github.com/CSB5/shotgun-metagenomics-pipeline>). Read quality trimming was
307 performed using famas (<https://github.com/andreas-wilm/famas>, v0.10, --no-order-check), and
308 bacterial reads were identified by mapping to the human reference genome hg19 using bwa-mem
309 (v0.7.9a, default parameters).

310
311 Microbial community taxonomic profiles were obtained using MetaPhlAn (v2.0, default
312 parameters, relative abundance >0.01%) which provides relative abundances of bacteria, fungi
313 and viruses at different taxonomic levels. The Shannon diversity index was computed from
314 species-level taxonomic profiles using the function diversity from the R library vegan. The
315 detection of antibiotic resistance genes was performed using SRST2 (v0.1.4, fraction of gene
316 covered >99%) using the predefined ARGannot database.

317

318

319 Supplementary Table 1: Carbapenamase producing *Enterobacteriaceae* and associated plasmids
 320 carried by the participants throughout the study period

		N = 21*
CPE species		
<i>Klebsiella pneumoniae</i> (%)		18 (85.7)
<i>Eschericia coli</i> (%)		16 (76.2)
<i>Enterobacter spp</i> (%)		5 (23.8)
<i>Citrobacter spp</i> (%)		3 (14.3)
	Co-colonization by >1 CPE species during follow up	15 (71.4)
Types of carbapenem-resistance genes		
OXA-48 (%)		11 (52.4)
KPC (%)		8 (38.1)
NDM-1 (%)		3 (14.3)
IMP (%)		2 (9.5)

	Co-colonization by >1 type of plasmid during follow up	3 (14.3)
--	--	----------


321 *Percentages refer to proportion of participants carrying the bacterial species or carbapenem-
 322 resistance genes. A single participant may carry more than one type of bacterial species or
 323 carbapenem-resistance genes during the observational period.

324

325 Supplementary Figure 1: Multistate Markov models for the analysis of CPE carriage

326

Multistate Model 1:
 Two states with carbapenamase-producing Enterobacteriaceae (CPE) carrying state and CPE non-carrying state




Legend

State 0: Not colonized with CPE
 State 1: Colonized with CPE

α : Colonization rate
 γ : Decolonization rate

Multistate Model 2:
 Four states with CP-E coli and CP-Klebsiella carrying states and CPE non-carrying state



Legend

State 00: Not colonized with CPE
 State 01: Colonized with CP- E. coli
 State 10: Colonized with CP- Klebsiella
 State 11: Colonized with CP- E.coli and CP-Klebsiella

α_k : Colonization rate of CP-Klebsiella
 γ_k : Decolonization rate of CP-Klebsiella
 α_e : Colonization rate of CP-E. coli
 γ_e : Decolonization rate of CP-E. coli

327

328

329 To estimate rates of colonization and duration of carriage, we modeled colonization and carriage
330 dynamics using multi-state Markov models. First, we considered CPE to be a homogeneous
331 bacterial group and at any sampling time point patients belonged to one of two states: “non-
332 colonised” or “colonised “. Secondly, we considered CPE by species with patients being “not
333 colonized by any CPE”, “colonized by CP-*E. coli*”, “colonized by CP-*K. pneumoniae*” or
334 colonised by “both CP-*E. coli* and *K. pneumoniae*”, resulting in a four-state Markov model. In
335 either models, transitions from one state to another was governed by a $K \times K$ intensity matrix Q .
336 For $r \neq s$, the rate of transition from state r to state s , $q_{rs} = Q[r, s]$ was modelled by the linear
337 equation:

$$\log(q_{rs}) = \beta_0 + \sum_{i=1}^D \beta_i \times X_i$$

338

339

340

341 where $\{X_1, X_2, \dots, X_D\}$ is a set of covariates.

342

343 For the two-state homogeneous CPE modelled we included age, taking antibiotics during follow-
344 up, Charlson comorbidity index, co-colonization with other multidrug resistant organisms,
345 infection with CPE, readmission, Shannon diversity index and presence of urinary catheter as
346 covariates.

347

348 The rate of remaining in state r was estimated by:

$$- \sum_{s \neq r}^k q_{rs}$$

349

350

351 We implemented the models in STAN modelling language within the R environment. We used
352 $N\sim(0,1)$ as prior distributions for parameters estimates, while posterior distributions were
353 sampled using the Hamiltonian Markov Chain Monte Carlo method. The prior is a generic
354 weakly informative prior as recommended by Rstan which contains enough information to
355 regularize i.e. rule out unreasonable values but is not so narrow as to rule out probable values
356 (Gelman, Github. 2019). Posterior distributions were sampled from 4 chains run over 20,000
357 iterations (including 10,000 burn-in) and we assessed model convergence using the Gelman-
358 Rubin convergence diagnostic statistic and through visualization of trace plots.

359
360 Supplementary Table 2: Rates of the four-state multistate model with CP-*E. coli*, CP-*Klebsiella*,
361 carrying both CP-*E. coli* and CP-*Klebsiella* (Both), CPE-non-carrying state (None)


	Event /day	95% CrI
CP- <i>E. coli</i> to None	0.018	0.007 – 0.031
CP- <i>Klebsiella</i> to None	0.030	0.016 – 0.050
CP- <i>E. coli</i> to Both	0.041	0.018 – 0.078
CP- <i>Klebsiella</i> to Both	0.045	0.019 – 0.087
Both to CP- <i>E. coli</i>	0.037	0.014 – 0.076
Both to CP- <i>Klebsiella</i>	0.040	0.018 – 0.073

362

363

364 Supplementary Figure 2: Associations of potential risk factors of CPE colonization and

365 decolonization rate.



366


367 MDRO: Multidrug resistant organisms including methicillin-resistant *Staphylococcus aureus*,

368 vancomycin-resistant *Enterococcus*, carbapenem-resistant *Enterobacteriaceae*, carbapenem-

369 resistant *Acinetobacter baumannii* and carbapenem-resistant *Pseudomonas aeruginosa*.

370

371 Supplementary Figure 3: Rates of the four-state multistate model where CP-*E. coli* and CP-
372 *Klebsiella pneumoniae* are separate states



373

374

375

